A vote on the Biosecure Act in the U.S. House of Representatives early next week shines the spotlight back on legislation seeking to rein in Chinese CDMOs and genomics companies, as Congress returns to work. On the latest BioCentury This Week podcast, BioCentury’s editors handicap the legislation’s chances of passage in the House and Senate and assess what’s at stake for the law authorizing rare pediatric disease priority review vouchers.
They also discuss the results of BioCentury’s snap poll gauging the biopharma industry’s reaction to the IRA Medicare drug price negotiation program, recalling the latest trends among pharma’s deals with biotechs over the past 12 months. Plus, a preview BioCentury’s annual Back to School package, next week’s new Grand Rounds R&D conference and highlights from this month’s Distillery roundup of translational papers.

View full story: https://www.biocentury.com/article/653385

00:00 - Introduction
01:36 - Biosecure on Deck
05:21 - Priority Review Vouchers
08:59 - BioCentury IRA Survey
17:55 - Back to School: Target Discovery
20:38 - Translational Highlights

Have a question? Send us a text!

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

BioCentury This Week

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery